Meiji Yasuda Asset Management Co Ltd. Sells 3,905 Shares of Boston Scientific Corporation $BSX

Key Points

• Meiji Yasuda Asset Management Co Ltd. reduced its stake in Boston Scientific by 4.0% in Q1, holding 92,650 shares valued at $9.3 million after selling 3,905 shares.
• Boston Scientific's analysts have a consensus rating of "Buy" with a target price averaging $117.50, including recent upgrades by Barclays and Citigroup.
• The company reported a 22.8% increase in quarterly revenue year-over-year, with EPS at $0.75, surpassing estimates and demonstrating strong financial performance.

Meiji Yasuda Asset Management Co Ltd. trimmed its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 4.0% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 92,650 shares of the medical equipment provider's stock after selling 3,905 shares during the period. Meiji Yasuda Asset Management Co Ltd.'s holdings in Boston Scientific were worth $9,347,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in BSX. GAMMA Investing LLC grew its position in Boston Scientific by 11,720.3% in the first quarter. GAMMA Investing LLC now owns 2,577,887 shares of the medical equipment provider's stock worth $260,057,000 after acquiring an additional 2,556,078 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Boston Scientific by 18.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,839,362 shares of the medical equipment provider's stock worth $968,172,000 after acquiring an additional 1,709,461 shares in the last quarter. Vanguard Group Inc. grew its position in Boston Scientific by 1.3% in the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock worth $13,577,311,000 after acquiring an additional 1,697,945 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Boston Scientific by 18.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider's stock worth $1,070,387,000 after buying an additional 1,664,108 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in shares of Boston Scientific by 161.9% in the first quarter. Assenagon Asset Management S.A. now owns 2,485,696 shares of the medical equipment provider's stock worth $250,757,000 after buying an additional 1,536,663 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Boston Scientific Stock Performance

NYSE:BSX traded down $1.63 during trading hours on Friday, hitting $102.71. 10,541,837 shares of the company traded hands, compared to its average volume of 6,118,901. The stock has a market capitalization of $152.19 billion, a price-to-earnings ratio of 61.14, a P/E/G ratio of 2.51 and a beta of 0.65. Boston Scientific Corporation has a twelve month low of $80.64 and a twelve month high of $109.50. The firm has a 50-day moving average of $104.86 and a 200 day moving average of $102.26. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business's quarterly revenue was up 22.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the sale, the executive vice president owned 23,600 shares of the company's stock, valued at $2,469,268. The trade was a 42.32% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Edward J. Ludwig sold 4,000 shares of the business's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the sale, the director directly owned 18,479 shares in the company, valued at $1,959,328.37. This trade represents a 17.79% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 174,214 shares of company stock worth $18,397,457. Corporate insiders own 0.50% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Royal Bank Of Canada restated an "outperform" rating on shares of Boston Scientific in a research note on Thursday, July 24th. Oppenheimer upgraded shares of Boston Scientific from a "market perform" rating to an "outperform" rating and boosted their price objective for the stock from $118.00 to $125.00 in a research note on Monday, September 8th. Citigroup restated a "buy" rating and issued a $125.00 price objective (up from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. Raymond James Financial boosted their price objective on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research note on Thursday, July 24th. Finally, Jefferies Financial Group restated a "hold" rating on shares of Boston Scientific in a research note on Monday, July 21st. Three analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of "Buy" and a consensus target price of $118.04.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.